Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Merck | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Merck

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Merck

3Q Revenues: $10.6 billion  (-4%)

3Q Earnings: $842 million (-27%)

YTD Revenues: $31.8 billion (-3%)

YTD Earnings: $4.6 billion (+24%)

Comments: Pharmaceutical sales were $9.1 billion in the quarter, down 4%. JANUVIA/JANUMET sales were up 5% to $1.4 billion. REMICADE sales were up 5% to $604 million. ZETIA/VYTORIN sales were down 3% to $1.0 billion. GARDASIL were down 11% to $590 million. NASONEX and SINGULAIR sales were down 12% and 22% to $261 million and $218 million, respectively. Consumer Care sales were down 9% to $401 million in the quarter. Results include $425 million of lower sales due to divestitures and the termination of the joint venture with AstraZeneca.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters